Insights+: EMA Marketing Authorization of New Drugs in August 2023

Shots: The EMA approved 5 New Chemical Entity (NCE) and 6 Biologic Drugs in August 2023, leading to treatments for patients and advances in the healthcare industry In August 2023, the major highlight drugs were Aquipta (atogepant) approved for the preventive treatment of migraine in adults & Opdivo (nivolumab) as an adjuvant treatment for completely…

BySenior EditorSeptember 28, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Shots: The EMA approved 9 New Chemical Entity (NCE) and 5 Biologic Drugs in July 2023, leading to treatments for patients and advances in the healthcare industry In July 2023, the major highlights drugs were Soliris approval for refractory generalised myasthenia gravis and Trodelvy for pre-treated HR+/HER2- metastatic breast cancer PharmaShots has compiled a list…

BySenior EditorAugust 24, 2023

THOUGHTSPOT

Social Media Listening in Pharmaceutical Industry

Shots: When it comes to embracing new-age technologies, the pharmaceutical industry always remains on the front foot. Galvanized by novel technological advances and innovations, the pharmaceutical industry is forging ahead at a momentous pace Social media listening fosters the use of leveraging several social media platforms to gather insights, resolve queries, carry out online market…

BySaurabh ChaubeyAugust 8, 2023

INSIGHTS+

Top Performing Drug – Ocrevus (July Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMS PharmaShots presents…

BySenior EditorJuly 26, 2023

THOUGHTSPOT

Intelligent Automation in Pharmaceutical Industry (AI & ML)

Shots: Driven by the influx of life-changing innovations and technological advances, the pharmaceutical industry is forging ahead at a momentous pace. With the impelling Pharma 4.0, automation has now been embedded in various aspects of current business practices Delving deeply into the importance of automation, primarily focusing on AI & ML, PharmaShots unveils its eight-step…

BySaurabh ChaubeyJune 6, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in April 2023

Shots: The EMA approved 8 New Chemical Entity (NCE) and 3 Biologic Drugs in April 2023, leading to treatments for patients and advances in the healthcare industry In April 2023, the major highlights drugs were Rinvoq’s Approval for active Crohn's Disease, Opzelura for non-segmental vitiligo with facial involvement in adults and adolescents PharmaShots has compiled…

BySenior EditorMay 25, 2023

INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots: With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…

BySenior EditorApril 13, 2023

TOP 20

Top 20 BioPharma Companies based on 2022 Total Revenue

Shots: Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. However, the previous year was difficult for biopharma companies as the segment saw multiple insolvencies. Amidst all kinds of obstacles, many companies have sustained themselves to meet the market…

ByPrince GiriApril 12, 2023

TOP 20

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Some companies accept the offered period and open doors to biological drugs or biosimilars. In…

ByPrince GiriMarch 29, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Shots: The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industry In February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndrome PharmaShots has compiled…

BySenior EditorMarch 23, 2023

Insights+: EMA Marketing Authorization of New Drugs in August 2023

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Top Performing Drug – Ocrevus (July Edition)

Intelligent Automation in Pharmaceutical Industry (AI & ML)

Insights+: EMA Marketing Authorization of New Drugs in April 2023

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Top 20 BioPharma Companies based on 2022 Total Revenue

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Contact US

FOLLOW US